Rapid Micro Biosystems (RPID) Preferred Stock Liabilities (2020 - 2021)
Rapid Micro Biosystems' (RPID) quarterly Preferred Stock Liabilities came in at $235.8 million in Q2 2021, up 60.1% year-on-year from $147.3 million in Q2 2020, and up 0.86% quarter-over-quarter from $233.8 million in Q1 2021.
Rapid Micro Biosystems (RPID) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Rapid Micro Biosystems has disclosed Preferred Stock Liabilities across 2 years of filings, most recently posting $235.8 million for Q2 2021.
- Preferred Stock Liabilities for Q2 2021 came in at $235.8 million, up 60.1% year-over-year; the trailing twelve-month figure through Jun 2021 was $235.8 million (up 60.1% YoY), and the FY2020 annual result was $4.1 million, changed N/A from the prior year.
- Preferred Stock Liabilities came in at $235.8 million for Q2 2021 at Rapid Micro Biosystems, up from $233.8 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $235.8 million in Q2 2021 to a low of $4.1 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | - |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | - |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | - |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | - |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | - |
| 10 | Rapid Micro Biosystems | 77.24 Mn | 54.29 Mn | 371,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 235.84 Mn |
| Mar 31, 2021 | 233.83 Mn |
| Dec 31, 2020 | 4.12 Mn |
| Sep 30, 2020 | 149.55 Mn |
| Jun 30, 2020 | 147.31 Mn |